GlassScriptPhysician profile
Brock Davis
NPI 1548909534
$4,457.89
in general payments reported to CMS, 2019-2025
24 companies · $1,689 in 2025
The $1,689 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $411 · 2024: $2,358 · 2025: $1,689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,179 · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,178.91 |
| Education | $278.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $644.75 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $483.44 | 2023-2025 | Sotyktu |
| Lilly USA, LLC | $389.65 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $384.89 | 2023-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $280.48 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $262.56 | 2023-2025 | Winlevi, Absorica Ld, Ilumya |
| Incyte Corporation | $231.28 | 2024-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $220.19 | 2024 | Dupixent, Libtayo |
| Janssen Scientific Affairs, LLC | $216.15 | 2024-2025 | Tremfya |
| Galderma Laboratories, L.P. | $180.68 | 2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $175.82 | 2023-2025 | Zoryve |
| Pfizer INC. | $169.14 | 2024-2025 | |
| Dermavant Sciences, INC. | $136.28 | 2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $129.44 | 2025 | |
| Amgen INC. | $114.16 | 2024-2025 | Otezla, Otezla |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Eli Lilly and Company | $99.00 | 2025 | |
| Genentech USA, INC. | $57.73 | 2023-2024 | Erivedge |
| Janssen Biotech, INC. | $55.33 | 2024-2025 | Tremfya |
| Viiv Healthcare Company | $34.71 | 2023 | Rukobia |
| Mimedx Group, INC. | $30.68 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.25 | 2024 | Spevigo |
| Organon LLC | $20.48 | 2025 | |
| Biofrontera INC. | $14.81 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brock Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.